Wed, Jul 23, 2014, 8:59 AM EDT - U.S. Markets open in 31 mins.

Recent

% | $
Click the to save as a favorite.

Cubist Pharmaceuticals Inc. Message Board

  • stevencath@sbcglobal.net stevencath Sep 10, 2009 11:58 PM Flag

    TELANVANCIN if FDA OK does matter *********

    Cubist is going to make 25% to 35% per qtr in the US with competition now ( 4 now and another with possibly Theravance )
    Theravance possibly( if OK’d to sell) not to sell to pregnanted woman or young kids.---------
    Also CUBICIN is growing selling against taking main ---competition ---Vancomycin that genereic antibiotic and has long been the treatment of last resort. I don’t get this -----we are working about TEVA pharm. and has to court in thirty months (which CBST is covered by PATENDED)
    What I’m getting out is ----(CBST) will sell CUBICIN in the US -----also Phizer Inc drug company and Vancomycin generic drug are the largist companys in competition with CUBIST and (CBST) is in high growth 25% to 35% per qtr. ---------CBST does don’t have to work abount ----------Theravance getting an ok on its drug ( not safe to sell on pregnanted woman or young kids) is something CBST -------have to worry about ------
    BY SWNV

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CBST
65.70+0.74(+1.14%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.